- Home
- KYMR vs JANX Comparison
KYMR vs JANX Comparison
Compare KYMR & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KYMR
- JANX
- Stock Information
- Founded
- KYMR 2015
- JANX 2017
- Country
- KYMR United States
- JANX United States
- Employees
- KYMR N/A
- JANX N/A
- Industry
- KYMR Medicinal Chemicals and Botanical Products
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- KYMR Health Care
- JANX Health Care
- Exchange
- KYMR Nasdaq
- JANX Nasdaq
- Market Cap
- KYMR 2.7B
- JANX 2.2B
- IPO Year
- KYMR 2020
- JANX 2021
- Fundamental
- Price
- KYMR $36.81
- JANX $36.01
- Analyst Decision
- KYMR Buy
- JANX Strong Buy
- Analyst Count
- KYMR 15
- JANX 11
- Target Price
- KYMR $55.27
- JANX $83.09
- AVG Volume (30 Days)
- KYMR 456.1K
- JANX 821.6K
- Earning Date
- KYMR 02-27-2025
- JANX 03-07-2025
- Dividend Yield
- KYMR N/A
- JANX N/A
- EPS Growth
- KYMR N/A
- JANX N/A
- EPS
- KYMR N/A
- JANX N/A
- Revenue
- KYMR $87,563,000.00
- JANX $13,049,000.00
- Revenue This Year
- KYMR N/A
- JANX $39.66
- Revenue Next Year
- KYMR $32.89
- JANX N/A
- P/E Ratio
- KYMR N/A
- JANX N/A
- Revenue Growth
- KYMR 86.92
- JANX 54.12
- 52 Week Low
- KYMR $29.24
- JANX $14.68
- 52 Week High
- KYMR $53.27
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- KYMR 42.51
- JANX 34.78
- Support Level
- KYMR $36.67
- JANX $36.13
- Resistance Level
- KYMR $38.24
- JANX $38.13
- Average True Range (ATR)
- KYMR 1.78
- JANX 2.52
- MACD
- KYMR 0.06
- JANX 0.08
- Stochastic Oscillator
- KYMR 51.81
- JANX 5.71
About KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer.